Niche start-ups spearheading cell and gene therapy innovation
Smaller companies targeting rare and extremely specific treatment areas are leading the charge in this emerging market.
Niche start-ups are driving innovation in the cell and gene therapy sector, according to a recent market report.
Cell and gene therapies are considered some of the most lucrative opportunity areas for biopharmaceutical developers due to the broad range of genetic diseases and significant unmet need for curative interventions.
Medical science has traced thousands of clinical conditions to a genetic cause, while cancer, which is considered among the leading causes of death worldwide, also has genetic origins.
The report, ‘Investor Series: Opportunities in the Cell and Gene Therapy Market’, found that start-ups targeting niche treatment areas are driving innovation in the sector, while big pharma players are also actively acquiring capabilities related to upcoming advanced therapy medical products (ATMPs). The first gene therapy trial was conducted in 1990 and it took almost three decades for the first of such interventions to enter the market.
Among several companies capitalizing on the market is Swiss multinational Novartis, whose product for the treatment of spinal muscular atrophy (ZOLGENSMA) generated net revenues of approximately $1.35 billion in 2021 alone. Another is US biotech bluebird bio, whose gene therapy was given a stamp of approval this week by US Food and Drug Administration (FDA) advisers. If it goes to market, it will be the third gene therapy to be made available in the United States.
The report notes that R&D activities slowed in the sector during the COVID-19 pandemic - a consequence of complex manufacturing protocols, extensive logistical considerations and supply chain-related concerns. However, the field still witnessed a considerable inflow of capital, with over $21 billion invested into various companies since the start of the pandemic.
There are currently more than 1,200 product candidates in various stages of development and some experts suggest that by 2025, the US FDA may start approving around 10 to 20 cell and gene therapy products annually.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance